Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints
Category: #health  | By Mateen Dalal  | Date: 2019-09-09 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Medtronic’s IN.PACT AV Access trial meets effectiveness endpoints

IN.PACT AV DCB showed encouraging results in the treatment of AV Fistulae Lesions in Renal Disease Patients at its last stage.

Medtronic plc, one of the world’s biggest medical device companies, has recently announced outcomes from its IN.PACT AV Access clinical trials assessing the PTA (percutaneous transluminal angioplasty) against the IN.PACT™ AV™ DCB (drug-coated balloon) in subjects with non-stented or de novo restenotic AV (arteriovenous) fistulae lesions.

Reportedly, the trials recently achieved its effectiveness endpoints and primary safety, presenting the data at the CIRSE (Cardiovascular and Interventional Radiology Society of Europe) annual meeting in Spain.

Speaking on the move, Andrew Holden, M.D., Associate Professor of Radiology at Auckland University and Director of Interventional Radiology at Auckland Hospital, said that limiting the frequency and maintaining patency of reinterventions demanded AV access sites to properly function remains the major treatment challenges for physicians doctoring AV fistulae lesions.

He said that these results show the potential of IN.PACT AV DCB in addressing these crucial issues and in improving the quality of life of patients going through dialysis.

For the uninitiated, AV fistulae, also known as AV access sites, was developed and used to provide hemodialysis to patients with ESRD (end-stage renal disease). As time passes, vessel restenosis restricts the capability to use AV fistulae efficiently. Hence, in order to rebuild function, patients frequently go through several AV fistula maintenance procedures each year. 

However, the need for repeated reinterventions can lead to a major disruption in serious hemodialysis care and would raise the costs of the healthcare system. Additionally, drug-coated balloons could extend the time between reinterventions by sustaining AV access site patency, increasing the patient’s constant access to dialysis care.

According to sources, the primary effectiveness endpoint reduced CD-TLR (clinically-driven target lesion revascularization). Moreover, additional endpoints involved collective target lesion revascularization, a number of interventions needed to sustain target lesion patency and access circuit primary patency.

Source Credit: http://newsroom.medtronic.com/news-releases/news-release-details/inpact-av-access-trial-meets-primary-safety-and-effectiveness

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted

Microsoft investigates Teams and Outlook outage that left users disrupted

By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

UK: Budget & basic items’ cost in supermarkets soar 20.3% in December

By Mateen Dalal

Britishers who rely on the budget-friendly aisles of supermarkets reportedly saw the biggest increases in food prices in the months leading up to Christmas, significantly outpacing those for luxury as well as premium brands, as per a survey. Accor...

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

Sun Cable shuts as $21B solar project to power S’pore hangs in balance

By Mateen Dalal

Sun Cable, the Singapore-based solar energy company, has reportedly entered voluntary administration, despite the financial support it received from billionaire investors. The company was supposed to be working on a A$30 billion (US$21 billion) solar...